Nili Weitzman-Bendersky

Barcode Diagnostics Ltd. is engaged in developing a product that assesses the efficacy of different cancer drugs directly on the tumor within the body to select the optimal personalized treatment for each patient. The company was founded by Ronen Eavri, Annie Sabbah, and Avi Schroeder in February 2017 and is headquartered in Nazareth, Israel.

Barcode Diagnostics Ltd. is engaged in developing a product that assesses the efficacy of different cancer drugs directly on the tumor within the body to select the optimal personalized treatment for each patient. The company was founded by Ronen Eavri, Annie Sabbah, and Avi Schroeder in February 2017 and is headquartered in Nazareth, Israel.

Barcode Diagnostics Ltd. is engaged in developing a product that assesses the efficacy of different cancer drugs directly on the tumor within the body to select the optimal personalized treatment for each patient. The company was founded by Ronen Eavri, Annie Sabbah, and Avi Schroeder in February 2017 and is headquartered in Nazareth, Israel.

Barcode Diagnostics Ltd. is engaged in developing a product that assesses the efficacy of different cancer drugs directly on the tumor within the body to select the optimal personalized treatment for each patient. The company was founded by Ronen Eavri, Annie Sabbah, and Avi Schroeder in February 2017 and is headquartered in Nazareth, Israel.

Barcode Diagnostics Ltd. is engaged in developing a product that assesses the efficacy of different cancer drugs directly on the tumor within the body to select the optimal personalized treatment for each patient. The company was founded by Ronen Eavri, Annie Sabbah, and Avi Schroeder in February 2017 and is headquartered in Nazareth, Israel.